Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia

Phase 2 Completed 172 enrolled Takeda

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy of lapaquistat acetate, once daily (QD), coadministered with a statin to lower lipid levels in Subjects with Hypercholesterolemia.

Timeline

Start: 2004-09
Primary completion: 2005-02
Completion: 2005-02

Publications

Results Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011 May 10;123(18):1974-85. doi: 10.1161/CIRCULATIONAHA.110.975284. Epub 2011 Apr 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lapaquistat acetate	Small molecule	100 mg	Oral
Comparator	Atorvastatin	Small molecule	10 mg	Oral
Comparator	Atorvastatin	Small molecule	20 mg	Oral

Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia

Summary

Timeline

Publications

Drugs

Indications